⌘+K

Company description

Alzinova is a Swedish clinical-stage biopharmaceutical company developing a therapeutic vaccine and monoclonal antibody against Alzheimer’s disease. The company identified a method that could specifically target the toxic elements in the brain – amyloid-beta oligomers – one of the underlying causes of Alzheimer’s disease.

Key industry drivers

  • Ageing population.

  • New innovative therapies.

  • Advancements in biomarkers and diagnostics.

Industry outlook

  • We expect the Alzheimer’s sector to experience robust growth, driven by emerging therapeutic targets, novel treatment modalities, and a supportive regulatory environment.

  • Key peers

    BioArctic, Alzecure Pharma

    Shareholders

    Name

    Capital

    Votes

    Maida Vale Capital AB

    13.1 %

    13.1 %

    Avanza Pension

    6.2 %

    6.2 %

    Nordnet Pensionsförsäkring

    6.0 %

    6.0 %

    Patrik Ahlvin

    3.7 %

    3.7 %

    Özlem Erdogdu Gül

    1.7 %

    1.7 %

    Marcus Milerud

    1.5 %

    1.5 %

    About DNB Carnegie Access

    DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

    Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

    Private Banking

    Tailored wealth management. Your financial future, personalized.

    Montrose

    A digital investment platform designed for passionate investors.

    DNB Carnegie

    Leading Nordic investment bank and wealth management.

    © Copyright DNB Carnegie Investment Bank AB